Ascentage Pharma of Suzhou has been approved to stage a Hong Kong IPO. The company, which has built a portfolio of seven clinical stage small-molecule candidates, bases its drug discovery on an expertise in protein-protein interactions. Its seven candidates are currently being tested in 20 Phase I and II trials in China, the US and Australia. One month ago, Ascentage raised $150 million in a Series C funding, bringing its total venture backing up to $240 million.
Source: China Biotoday
